Brief: Revive Therapeutics Announces Orphan Drug Designation For Cannabidiol In Treatment Of Autoimmune Hepatitis
27/06/2018 17:32
June 27 (Reuters) - Revive Therapeutics Ltd RVV.V :
* REVIVE THERAPEUTICS ANNOUNCES FDA GRANTS ORPHAN DRUG
DESIGNATION
FOR CANNABIDIOL IN THE TREATMENT OF AUTOIMMUNE HEPATITIS
Source text for Eikon: ID:nGNX6q6Qpp
Further company coverage: RVV.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure